ATHENS, Ga. & LOS GATOS, Calif.–(BUSINESS WIRE)–Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company enlisting the full breadth of the immune system to protect people from serious infectious diseases, today announced that management will be presenting and engaging in 1-1 meetings at the following upcoming investor conferences:
-
BioFuture
- October 6th, 2023 at 10:00 a.m. ET
- New York City, New York
- 1-1 partnering access: https://biofuture.com/one-to-one-meetings/
-
BIO Investor Forum
- October 18th, 2023 at 1:30 p.m. PT
- San Francisco, California
- 1-1 partnering access: https://bif.bio.org/bio-one-one-partnering
About Blue Lake Biotechnology
Blue Lake Biotechnology, Inc. and its affiliate, CyanVac LLC, are developing intranasal vaccines that enlist the full breadth of the immune system to keep people healthy, prevent serious infectious diseases, and save the lives of vulnerable populations. Our platform uses a proprietary parainfluenza virus 5 vector into which a foreign gene from a targeted pathogen is inserted. We have generated a robust clinical-stage pipeline of best-in-class vaccines designed to overcome the limitations of existing vaccine technologies. Our lead product candidates have demonstrated potential for high efficacy and lasting durability with few vaccine-related side effects.
Learn more at https://www.bluelakebiotechnology.com.
Contacts
Carolyn Hawley
Evoke Canale
carolyn.hawley@evokegroup.com
619-849-5382
Samuel Wu, Chief Business Officer
Blue Lake Biotechnology, Inc. and CyanVac LLC
swu@bluelakebiotechnology.com
650-427-0166